ArticleFrontiers in immunology2022

Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine.

Shi-Hao Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.